ATE324903T1 - Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten - Google Patents

Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten

Info

Publication number
ATE324903T1
ATE324903T1 AT03003687T AT03003687T ATE324903T1 AT E324903 T1 ATE324903 T1 AT E324903T1 AT 03003687 T AT03003687 T AT 03003687T AT 03003687 T AT03003687 T AT 03003687T AT E324903 T1 ATE324903 T1 AT E324903T1
Authority
AT
Austria
Prior art keywords
bacterial endotoxin
fetal
compositions containing
optional additional
fetal hemoglobin
Prior art date
Application number
AT03003687T
Other languages
English (en)
Inventor
Otto Westphal
Alfred Hartmann
Silke Mueller
Thierry Waelli
Jean-Pierre Mach
Wolfgang Bessler
Antonio Verdini
Petra Hoffmann
Ulrich Zaehringer
Christian Alexander
Artur J Ulmer
Reginald Gorczynski
Original Assignee
Clinique La Prairie Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinique La Prairie Res Sa filed Critical Clinique La Prairie Res Sa
Application granted granted Critical
Publication of ATE324903T1 publication Critical patent/ATE324903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03003687T 2003-02-18 2003-02-18 Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten ATE324903T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003687A EP1449535B1 (de) 2003-02-18 2003-02-18 Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten

Publications (1)

Publication Number Publication Date
ATE324903T1 true ATE324903T1 (de) 2006-06-15

Family

ID=32731533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03003687T ATE324903T1 (de) 2003-02-18 2003-02-18 Zusammensetzungen enthaltend fötales hämoglobin und bakterielles endotoxin und fakultativ zusätzliche fötale leberkomponenten

Country Status (20)

Country Link
US (1) US7968103B2 (de)
EP (2) EP1449535B1 (de)
JP (1) JP4619352B2 (de)
KR (1) KR101102481B1 (de)
CN (1) CN1750840A (de)
AT (1) ATE324903T1 (de)
AU (1) AU2004212703C1 (de)
BR (1) BRPI0407311B8 (de)
CA (1) CA2514485C (de)
DE (1) DE60304989T2 (de)
DK (1) DK1449535T3 (de)
ES (1) ES2263859T3 (de)
IL (1) IL169760A (de)
IS (1) IS2294B (de)
MX (1) MXPA05008797A (de)
NO (1) NO334003B1 (de)
NZ (1) NZ541417A (de)
PL (1) PL211789B1 (de)
RU (1) RU2366449C2 (de)
WO (1) WO2004073728A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080070971A1 (en) * 2006-03-06 2008-03-20 Wang Xiang H Medical Use of Bilirubin and its Structural Analogues
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
AU2010239463B2 (en) 2009-04-20 2016-12-08 Galenbio, Inc. Compositions for transfection of biomolecules into cells
EP2789343A1 (de) * 2013-04-11 2014-10-15 Clinique La Prairie Neue hämoglobinabgeleitete peptidbasierte pharmazeutische Zusammensetzungen
EP3019186A4 (de) * 2013-07-12 2017-03-29 Patrick J. Casey Verfahren zur gewinnung, lagerung und speicherung von proteinen aus einer feto-plazentalen einheit eines säugetiers sowie verwendung solcher proteine in zusammensetzungen und medizinischen behandlungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
WO1987006830A1 (en) 1986-05-09 1987-11-19 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
DE69021791T2 (de) 1989-06-30 1996-05-02 American Cyanamid Co Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
JPH0690745A (ja) * 1990-08-20 1994-04-05 Chiba Seifun Kk Ｌｐｓ産生菌、ｌｐｓ、ｌｐｓを含む医薬及び動物薬
CA2049548C (en) 1990-08-20 2002-07-02 Kiyoshi Yoshimura Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines
JPH0499481A (ja) * 1990-08-20 1992-03-31 Chiba Seifun Kk 新規細菌、新規ｌｐｓ、新規免疫機能活性化剤、新規動物用免疫機能活性化剤
JPH04187640A (ja) * 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
EP0539610A1 (de) * 1991-10-26 1993-05-05 Torf Establishment Verfahren und Zusammensetzung zur Bestimmung der Immunologischen Aktivität von aktiven Substanzen enthaltende Lösungen
JP3199081B2 (ja) * 1992-11-13 2001-08-13 味の素株式会社 抗腫瘍剤
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
US5648343A (en) 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US5580724A (en) * 1994-03-25 1996-12-03 Board Of Regents, The University Of Texas System Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
ATE200893T1 (de) * 1995-10-06 2001-05-15 Vertex Pharma Butyrat-medikamentvorstufen der milchsäure
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EP0856592A1 (de) 1997-02-04 1998-08-05 N.V. Bekaert S.A. Beschichtung enthaltende Filme aus diamantartigem Kohlenstoff und diamantartigem Nanokomposit
US6228471B1 (en) * 1997-02-04 2001-05-08 N.V. Bekaert S.A. Coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
JP5099951B2 (ja) * 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
PT2295968E (pt) * 1999-12-03 2013-01-09 Baxter Int Teste de pirogenicidade para utilização com sistemas automatizados de imunoensaio
AU783099B2 (en) * 2000-01-07 2005-09-22 Rohm Gmbh & Co. Kg Selective activation of a TH1 or TH2 lymphocyte regulated immune response
WO2002017965A1 (en) * 2000-08-28 2002-03-07 Akira Awaya Medicinal compositions
DE10103211C1 (de) * 2001-01-24 2002-07-18 Ursula Kastner Kulturmedium

Also Published As

Publication number Publication date
EP1449535B1 (de) 2006-05-03
PL378573A1 (pl) 2006-05-02
MXPA05008797A (es) 2006-05-25
IS7940A (is) 2005-07-18
EP1449535A1 (de) 2004-08-25
DE60304989T2 (de) 2007-03-29
CN1750840A (zh) 2006-03-22
JP2006518350A (ja) 2006-08-10
NO20054087D0 (no) 2005-09-02
RU2005126141A (ru) 2006-01-27
CA2514485A1 (en) 2004-09-02
IL169760A (en) 2012-09-24
PL211789B1 (pl) 2012-06-29
AU2004212703B2 (en) 2008-10-30
CA2514485C (en) 2013-11-05
WO2004073728A2 (en) 2004-09-02
BRPI0407311B1 (pt) 2020-12-29
NO334003B1 (no) 2013-11-11
EP1601371A2 (de) 2005-12-07
KR20050111596A (ko) 2005-11-25
AU2004212703C1 (en) 2009-05-21
BRPI0407311B8 (pt) 2021-11-30
KR101102481B1 (ko) 2012-01-05
NO20054087L (no) 2005-11-08
AU2004212703A1 (en) 2004-09-02
RU2366449C2 (ru) 2009-09-10
WO2004073728A3 (en) 2004-10-07
DE60304989D1 (de) 2006-06-08
DK1449535T3 (da) 2006-09-11
BRPI0407311A (pt) 2006-02-21
ES2263859T3 (es) 2006-12-16
IS2294B (is) 2007-10-15
US7968103B2 (en) 2011-06-28
US20080075742A1 (en) 2008-03-27
JP4619352B2 (ja) 2011-01-26
NZ541417A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
SG163517A1 (en) Antiviral compounds and methods
NO941786L (no) Uretaner og ureaer som induserer cytokinproduksjon
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
MX2010006046A (es) Moduladores de gamma secretasa.
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
IL176298A (en) Imidazo [5,4 – c] pyridine compounds, preparations containing them and these compounds for use in the treatment and prevention of viral infection
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
MY144318A (en) Methods of treating hiv infection.
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
WO2006066079A3 (en) Pyridazinone compounds
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
WO2010052575A3 (en) Ngna compositions and methods of use
DE60304989D1 (de) Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
WO2006034001A3 (en) Methods of treating hiv infection
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
EP1682518A4 (de) Dikationische triarylanaloga als mittel gegen protozoen
GB0123276D0 (en) Uses of agents that bind immune-system components
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
HK1121496A (en) Novel pharmaceutical compositions for the treatment of virus infection and cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1449535

Country of ref document: EP